Latest News

How does GBV affect vulnerability to HIV?

Date: Monday, 21 June 2021
Time: 
18:00 CAT
Hashtag to use: 
#TBHIVCare
Where:
Twitter
Moderating account:
@TBHIVCare
Topic: How does GBV affect your vulnerability to HIV?

 

Join us for a 60-minute session with our panel experts. All stakeholders including healthcare workers, survivors and the public etc. locally and globally are welcome. The public transcript will be recorded by Symplur.

T1: What is the relationship between gender-based violence and HIV?
T2: How do gender roles contribute to vulnerability to gender-based violence and HIV infection?

T3: How do we differentiate between gender-based violence and intimate partner violence? Are they the same thing? If not, how are they different?

T4: Does GBV affect young people differently to older people?

T5: What can be done to address gender-based violence and reduce the risk of being infected with HIV?
CT: (Closing Thoughts): Do you have anything you want to add about the link between gender-based violence and HIV in South Africa?

 

HOW TO PARTICIPATE:

Start your answers with T1, T2, T3, T4 or CT for transcript purposes.
Answer only after the moderator prompts. Questions will be prompted every 10 minutes, but keep answers coming using the relevant T and number. Both panel experts and public attendees are encouraged to participate.
Use the #TBHIVCare hashtag in all tweets so you are visible to others in the chat.

Everyone is welcome to join locally and globally. Our transcript will be recorded on www.symplur.com.

Topic:

South Africa has one of the highest rates of gender-based violence (GBV) in the world. According to Stats SA one in five women (21%) has experienced physical violence by a partner, and according to ONE (global movement campaigning to end extreme poverty and preventable disease) the rate of femicide is equivalent to the rate of fatalities experienced by countries at war.

GBV puts women at risk of HIV. UNAIDS reports that in sub-Saharan Africa, women who have experienced intimate partner violence are 50% more likely to be living with HIV. Marginalised groups, such as female sex workers, transgendered people and women who use drugs experience even higher rates of GBV, and are also at greater risk of being infected with HIV.

As well as being a public health issue in its own right, GBV is therefore also intimately linked to other global pandemics, such as HIV and now, COVID-19. It is reported that during the first week of the COVID-19 lockdown in South Africa in 2020, reported cases of GBV rose by 30%.

Some of the areas where improvements have been suggested are in policing, the economic empowerment of women and general community awareness.

Police’s handling of GBV cases has been criticized, with some reports that police are sometimes unwilling to intervene in what is perceived to be a private matter. When marginalised groups such as transgender people, female sex workers or women who use drugs are involved, it is even more difficult to access police support due to the strained relationship that often exists between these groups and law enforcement.

Some GBV survivors are unable to remove themselves from abusive relationships because they are financially dependent on their abusers. The systemic economic empowerment of women may therefore be one way to address GBV.

With GBV such a vastly widespread issue that presents a real, daily threat for millions of people around the country, it appears that communities have not yet rejected GBV as unacceptable behaviour. More awareness is needed to combat the “abantu bazothini syndrome” (“what will people say”) or none of my business attitude that keeps many from speaking out against GBV.

Sound the alarm! The clock is ticking: let’s prevent, find and end TB!

In support of the national theme for World TB Day 2021 The clock is ticking to find, treat and end TB, TB HIV Care is asking the country, to “sound the alarm. Raise your voice and make a noise to show that time is running out to meet our commitments to end TB.”

We’re asking you to commit to sound the alarm by signing an online pledge committing to:

  • Setting your phone or watch alarm to go off at 08h00 from 17th to 24th March
  • Blowing a vuvuzela at 08h00 from 17th to 24th March
  • Hooting your car at 08h00 from 17th to 24th March

In 2018, South Africa made commitments to meet certain TB targets by 2022 at the United Nations High-Level Meeting (UNHLM) on TB. With less than two years left to fulfil them, the clock is ticking. With the advent of the COVID-19 pandemic, TB has slipped back down the global health agenda, while simultaneously severely impacting on the delivery of TB-related health services. The National Institute of Communicable Diseases (NICD) noted a 30% drop in TB diagnosis in the first five months of the COVID-19 pandemic in the country. In a context where 42% of people sick with TB were already not being diagnosed and treated, this is seen by many as a crisis.

An important aspect of the 2022 UNHLM targets is a show of political leadership and coordination in the country by the formation of a multisectoral accountability framework for TB (MAF-TB). The clock is ticking to set up such a mechanism in South Africa, which could then ensure progress towards the other critical targets.

This campaign aims to sound the alarm on TB as a public health emergency and focus attention on the countdown to meeting South Africa’s targets to End TB.

For media enquiries: Alison Best 072 615 9192

Stop TB Partnership World TB Day 2021 toolkit

SANAC World TB Day 2021 toolkit

All you need to know about the COVID-19 vaccine

Vaccination has saved millions of lives and is one of the most successful public health interventions the world has ever seen. Vaccinating our children is one of the key acts we as parents take to ensure their health.

Many people have questions about the new COVID-19 vaccine that has just arrived in South Africa and will begin to be offered to health care workers in phase one of three phases.

The National Department of Health has developed excellent resources to answer these questions. We’ve extracted some below, but the full version and even more resources are available here.

What is a COVID-19 vaccine?

A vaccine is intended to provide immunity against COVID-19. In general, vaccines contain weakened or inactive parts of a particular organism that triggers an immune response within the body. This weakened version will not cause the disease in the person receiving the vaccine, but it will prompt their immune system to respond. Some vaccines require multiple doses, given weeks or months apart. This is sometimes needed to allow for the production of long-lived antibodies and development of memory cells. In this way, the body is trained to fight the specific disease-causing organism, building up memory against the pathogen so it can fight it in the future.

What is herd immunity?

When a lot of people in a community are vaccinated, the pathogen has a hard time circulating because most of the people it encounters are immune. So the more that others are vaccinated, the less likely people who are unable to be protected by vaccines are at risk of even being exposed to the harmful pathogens. This is called herd immunity. But no single vaccine provides 100% protection, and herd immunity does not provide full protection to those who cannot safely be vaccinated. But with herd immunity, these people will have substantial protection, thanks to those around them being vaccinated. Vaccinating not only protects yourself, but also protects those in the community who are unable to be vaccinated.

What process is followed before a vaccine is given to the public?

Before COVID-19 vaccines can be delivered: 1) The vaccines must be proven safe and effective in large clinical trials. 2) A series of independent reviews of the efficacy and safety evidence is required. 3) The evidence must also be reviewed for the purpose of policy recommendations on how the vaccines should be used. 4) An external panel of experts convened by WHO, called the Strategic Advisory Group of Experts on Immunization (SAGE), analyzes the results from clinical trials. 5) The panel then recommends whether and how the vaccines should be used. 6) Officials in individual countries decide whether to approve the vaccines for national use and develop policies for how to use the vaccines in their country based on the WHO recommendations.

What steps are taken to ensure the COVID-19 vaccine is safe?

COVID-19 vaccines go through a rigorous, multi-stage testing process, including large trials that involve tens of thousands of people. These trials, which include people at high risk for COVID-19, are specifically designed to identify any common side effects or other safety concerns. Once a clinical trial shows that a COVID-19 vaccine is safe and effective, a series of independent reviews of the efficacy and safety evidence is required, including regulatory review and approval in the country where the vaccine is manufactured, before WHO considers a vaccine product for prequalification. An external panel of experts convened by WHO analyzes the results from clinical trials, along with evidence on the disease, age groups affected, risk factors for disease, and other information. The panel recommends whether and how the vaccines should be used.

Are vaccines necessary to prevent the spread of COVID-19?

There is overwhelming scientific evidence that vaccination is the best defence against serious infections. Vaccines do not give you the virus, rather it teaches your immune system to recognise and fight the infection. The COVID-19 vaccine presents the body with instructions to build immunity and does not alter human cells. Vaccine have reduced the morbidity and mortality of infectious diseases such as smallpox, poliomyelitis, hepatitis B, measles, tetanus, whooping cough and pneumococcal conjugate across the world. Vaccinating enough people would help create herd immunity and stamp out the disease.

Are vaccines safe to use?

Vaccines undergo rigorous trials to ensure they are safe and effective. All vaccines go through a comprehensive approval process by medical regulators to ensure that they are safe. Pharmaceutical companies hand over all laboratory studies and safety trials to validate that the vaccine does work. Any safety concerns are picked up by regulators when reviewing the data. Vaccines are made to save lives – not to oppress, bewitch, possess or indoctrinate people.

Where is South Africa getting its first vaccine from?

South Africa will receive 1 million doses of the COVID-19 vaccine in January and 500,000 doses in February of the Oxford University-AstraZeneca vaccine from the Serum Institute of India (SII).

Who will get the COVID-19 vaccine first?

We will begin by vaccinating our country’s estimated 1.25 million healthcare workers.

How do we make sure COVID-19 vaccines are safe?

Government is working closely with South African Health Products Regulatory Authority (SAHPRA) to ensure there is no delay approving the vaccine for use. The Oxford University-AstraZeneca vaccine has already been approved by various regulators around the world and is being rolled out in other countries.

Who are our other vaccine suppliers?

We have also reached an agreement with the COVAX Facility to secure vaccines to immunise 10% of the population. These doses are expected at the beginning of second quarter of the year and we continue to work with various pharmaceuticals companies to ensure we immunise 67% of the population by the end 2021.

Was there a deliberate delay in acquiring a COVID-19 vaccine for South Africans?

There has been no deliberate delay to access the COVID-19 vaccine, as the situation remains fluid; all factors have to be taken into account. We are selecting vaccines on their safety and efficacy, ease of use, storage, distribution, supply sustainability and cost.

How will the vaccine be distributed?

Our rollout of the vaccine will take a three-phase approach that begins with the most vulnerable in our population. Our target is to vaccinate 67% of the population by the end of 2021, which will allow us to achieve herd immunity.

  • Phase 1 will focus on frontline healthcare workers
  • Phase 2 will vaccinate essential workers, persons in congregate settings, persons over 60 years and persons over 18 years with co-morbidities.
  • Phase 3 will focus on persons older than 18 years, targeting 22,500,000 of the population.

Who is purchasing the COVID-19 vaccine for South Africa?

Government will source, distribute and oversee the rollout of the vaccine. Government as the sole purchaser of vaccines will distribute it to provincial governments and the private sector. A national register for COVID-19 vaccinations will be established. The vaccination system will be based on a pre-vaccination registration and appointment system. All those vaccinated will be placed on a national register and provided with a vaccination card. A national rollout committee will oversee the vaccine implementation in both the public and private sectors.

Extracted from “All you need to know about COVID-19 and vaccines: A complete guide” South African National Department of Health. 2021

More resources